TMEM220: A Transmembrane Protein for Drug Targets and Biomarkers

Target Name: TMEM220

NCBI ID: G388335

TMEM220

TMEM220: A Transmembrane Protein for Drug Targets and Biomarkers

TMEM220 (Transmembrane protein 220) is a protein that is expressed in various tissues and organs in the human body. Its primary function is to regulate the movement of positively charged molecules into the cell, which is a process known as anion exchange. TMEM220 is a member of the superfamily of transmembrane proteins, which are a type of protein that spans the cell membrane and interacts with various intracellular and extracellular molecules.

Recent studies have identified TMEM220 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential applications of TMEM220 in more detail.

Biochemistry and Localization

TMEM220 is a 21-kDa protein that consists of 114 amino acid residues. It has a characteristic transmembrane structure, with a cytoplasmic tail that is involved in its stability and localization to the plasma membrane. TMEM220 is predominantly expressed in the brain, heart, pancreas, and skeletal muscles, and its levels are also increased in various diseases, including cancer.

Function and Diverse Roles in Cellular Physiology

TMEM220 plays a vital role in the regulation of anion exchange, which is a critical process for maintaining the electrical properties of cells. During anion exchange, TMEM220 helps to maintain the protonation of various amino acids, such as glutamic acid, which is essential for proper cellular signaling and metabolism.

In addition to its role in anion exchange, TMEM220 is involved in the regulation of various other cellular processes, including cell adhesion, migration, and the production of reactive oxygen species (ROS). It is also involved in the regulation of ion channels, which are responsible for the passage of charged particles into and out of cells.

Potential Drug Target and Biomarker

Several studies have identified TMEM220 as a potential drug target for various diseases. Its involvement in anion exchange makes it an attractive target for drugs that target ion channels and other processes that are involved in the regulation of electrolytes.

One of the most promising TMEM220-targeted drugs is a small molecule called NEDD8 (N-Acetyl-L-Glutamate). NEDD8 is a known inhibitor of the protein kinase CK2, which is involved in the regulation of many cellular processes, including anion exchange. By inhibiting CK2, NEDD8 can reduce the activity of TMEM220 and prevent it from regulating the movement of positive charges into cells.

In addition to its potential as a drug target, TMEM220 has also been identified as a potential biomarker for various diseases. Its increased expression in diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders, makes it a promising marker for these conditions.

Conclusion

TMEM220 is a transmembrane protein that plays a vital role in the regulation of various cellular processes, including anion exchange and ion channels. Its potential as a drug target and biomarker for various diseases makes it an attractive target for researchers and clinicians alike. Further studies are needed to fully understand the biology and applications of TMEM220, and to develop safe and effective drugs that target it.

Protein Name: Transmembrane Protein 220

The "TMEM220 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM220 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets